Close Window
Ebola Vaccine Aiming For Human Trials April 4, 2008
NIH Ebola Graphic
Within a week, a raised rash, often hemorrhagic (bleeding), spreads over Ebola victims. Hemorrahaging from the mucous membranes causes apparent bleeding from the mouth, nose, eyes and rectum.
A team of American and Canadian researchers say they have successfully tested several Ebola vaccines in monkeys and are attempting to create one that will protect humans from one of the world’s deadliest diseases.

“Successful human trials will mean that we can vaccinate health care workers and other key personnel during outbreaks of Ebola hemorrhagic fever, helping us to protect their lives and control the spread of the disease,” said Dr. Anthony Sanchez of the U.S. Centers for Disease Control and Prevention.

There have been more than 1,500 cases of Ebola in humans since the disease was first identified in the heart of Africa in 1976. The human mortality rate has been around 90 percent.

Symptoms include fever, headache, sore throat, weakness, joint and muscle aches, diarrhea, vomiting and stomach pain.

Because Ebola virus is so dangerous, producing and testing a vaccine is extremely challenging for the scientists.

One significant factor slowing down progress has been that there are only a very limited number of high containment facilities with staff capable and authorized to conduct the research.

Graphic: U.S. National Institutes of Health
Digg This